Data / Research funding / Neurofibromatosis

Neurofibromatosis: 91 NIH awards ($89.9M) to 47 organizations

Name: NIH and NSF awards on Neurofibromatosis
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

91 NIH awards ($89.9M) in the NIH spending category Neurofibromatosis, to 47 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards on Neurofibromatosis Watch Neurofibromatosis

Topic: NIH spending category

Awards

91 awards in the window.

Award	Agency	Institute or division	Fiscal year	Amount in window	Start	End	Principal investigator	Source
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)	NIH	National Cancer Institute	2021 to 2025	$3,076,366	April 1, 2021	March 31, 2026	CHI, PING	reporter.nih.gov
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$2,950,878	December 1, 2016	November 30, 2024	GUTMANN, DAVID H	reporter.nih.gov
Neuronal Regulation of Low-Grade Gliomagenesis	NIH	National Cancer Institute	2022 to 2025	$2,518,768	April 1, 2022	March 31, 2027	MONJE-DEISSEROTH, MICHELLE	reporter.nih.gov
NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$2,512,290	September 1, 2020	May 31, 2026	RAMESH, VIJAYA	reporter.nih.gov
T Cell Regulation of Low-Grade Glioma	NIH	National Cancer Institute	2022 to 2025	$2,353,237	September 9, 2022	August 31, 2027	GUTMANN, DAVID H	reporter.nih.gov
Developmental Origin, Injury and Epigenomic Regulation of NF1-Associated Peripheral Nerve Sheath Tumors	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$2,339,120	April 15, 2021	June 30, 2024	ZHU, YUAN	reporter.nih.gov
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$2,281,119	September 1, 2020	June 30, 2025	LARGAESPADA, DAVID ANDREW	reporter.nih.gov
Mitogenic Activities in Neurofibromatosis	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2025	$2,263,287	August 1, 1990	February 29, 2028	RATNER, NANCY	reporter.nih.gov
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention	NIH	National Cancer Institute	2021 to 2023	$2,148,196	September 25, 2019	August 31, 2025	LARGAESPADA, DAVID ANDREW	reporter.nih.gov
Quantitative MRI for Pediatric Optic Pathway Glioma Treatment Response	NIH	National Cancer Institute	2022 to 2024	$2,119,273	June 17, 2020	July 31, 2025	AVERY, ROBERT ANDREW	reporter.nih.gov
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2025	$2,097,360	March 1, 2022	February 28, 2027	DODD, REBECCA D	reporter.nih.gov
Identification of Novel Pathways Causing NF1-Driven Schwann Cell Tumors	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2025	$1,987,528	December 1, 2021	November 30, 2026	RATNER, NANCY	reporter.nih.gov
New Ways of Targeting K-Ras	NIH	National Cancer Institute	2021 to 2022	$1,950,085	April 1, 2016	March 31, 2023	MCCORMICK, FRANK PATRICK	reporter.nih.gov
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors	NIH	National Cancer Institute	2022 to 2025	$1,921,213	July 8, 2022	June 30, 2027	CICHOWSKI, KAREN M	reporter.nih.gov
The role of Neurofibromin 2 in heart failure	NIH	National Heart, Lung, and Blood Institute	2023 to 2025	$1,822,321	June 15, 2022	May 31, 2027	DEL RE, DOMINIC P	reporter.nih.gov
Therapeutic Targeting of Receptor Tyrosine Kinase Hierarchies in Schwann Cell Neoplasms	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$1,732,846	September 1, 2020	June 30, 2025	CARROLL, STEVEN L.	reporter.nih.gov
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment	NIH	National Cancer Institute	2023 to 2025	$1,725,555	June 12, 2023	May 31, 2028	PRATILAS, CHRISTINE ANNE	reporter.nih.gov
Etiology of musculoskeletal maladies in NF1	NIH	National Institute of Arthritis and Musculoskeletal and Skin Diseases	2021 to 2025	$1,710,720	April 1, 2021	February 28, 2026	ELEFTERIOU, FLORENT	reporter.nih.gov
MiR-155 and RUNX function in neurofibroma tumorigenesis and therapy	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2025	$1,702,017	July 1, 2016	June 30, 2027	WU, JIANQIANG	reporter.nih.gov
Nf2-dependent regulation of neuronal scaling in the developing cerebellum	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2025	$1,692,665	June 15, 2022	May 31, 2027	CHIZHIKOV, VIKTOR	reporter.nih.gov
Personalized risk assessment in Neurofibromatosis Type 1	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,690,880	April 1, 2023	March 31, 2027	GUPTA, ADITI	reporter.nih.gov
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$1,671,259	September 1, 2021	August 31, 2025	KISSIL, JOSEPH	reporter.nih.gov
Cellular and Molecular Mechanisms of Brain Dysfunction in NF1	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2024	$1,581,350	April 15, 2020	January 31, 2025	YANG, NAN	reporter.nih.gov
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2025	$1,531,238	July 1, 2022	June 30, 2027	CLAPP, DAVID W	reporter.nih.gov
Function of NF2/Merlin in regulation of the Hippo/Salvador/Warts growth control pathway	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,463,400	September 18, 2023	August 31, 2028	FEHON, RICHARD G	reporter.nih.gov
Targeting the Cancer Stem Cells in Malignant Peripheral Nerve Sheath Tumor	NIH	National Cancer Institute	2022 to 2025	$1,402,421	August 1, 2022	July 31, 2027	SUN, DAOCHUN	reporter.nih.gov
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,369,818	December 1, 2022	November 30, 2027	XU, LEI	reporter.nih.gov
Targeting HMGB1 to improve hearing andenhance therapy for Vestibular Schwannomas	NIH	National Institute on Deafness and Other Communication Disorders	2023 to 2025	$1,336,488	June 16, 2023	May 31, 2028	XU, LEI	reporter.nih.gov
Identification of novel therapeutic combinations for NF2 schwannomas	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,302,459	February 15, 2023	January 31, 2028	CLAPP, DAVID W	reporter.nih.gov
Inflammation and retinopathy of prematurity	NIH	National Eye Institute	2021 to 2023	$1,287,408	May 1, 2019	April 30, 2025	STANSFIELD, BRIAN KEVIN	reporter.nih.gov
AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma	NIH	National Institute of Neurological Disorders and Stroke	2025	$1,256,291	August 27, 2025	July 31, 2027	YANG, NA NORA	reporter.nih.gov
Identification of Germline Modifiers of Neurofibromatosis Type 1 Tumors	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$1,254,291	September 10, 2024	August 31, 2029	RATNER, NANCY	reporter.nih.gov
Preclinical Testing of PI3K Inhibitors for Vestibular Schwannomas	NIH	National Institute on Deafness and Other Communication Disorders	2021 to 2022	$1,195,641	July 1, 2018	June 30, 2025	FERNANDEZ-VALLE, CRISTINA MARIA	reporter.nih.gov
Midbrain pathways for visual hypersensitivity in neurofibromatosis type 1	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,174,260	July 15, 2023	May 31, 2028	ROBINSON, JOHN ELLIOTT	reporter.nih.gov
Investigating and Targeting Pathways of Malignant Peripheral Nerve Sheath Tumor (MPNST)	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2022	$1,172,024	July 1, 2019	June 30, 2024	ZHU, YUAN	reporter.nih.gov
Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs	NIH	National Cancer Institute	2024 to 2025	$1,144,229	March 11, 2024	February 28, 2029	TORRES, KEILA ENITT	reporter.nih.gov
Preclinical-clinical trials collaboration to effectively advance new combination therapies for atypical neurofibroma in neurofibromatosis type 1	NIH	National Cancer Institute	2023 to 2025	$1,120,521	February 7, 2023	January 31, 2027	CLAPP, DAVID W	reporter.nih.gov
Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2025	$1,115,713	October 11, 2022	February 28, 2027	TOMCHIK, SETH M	reporter.nih.gov
Genomics and Functional Characterization of NF1-mutated Lung Cancer	NIH	National Cancer Institute	2021 to 2022	$1,072,016	June 11, 2018	November 30, 2023	COLLISSON, ERIC	reporter.nih.gov
Enhanced auditory prosthesis using a penetrating auditory-nerve electrode	NIH	National Institute on Deafness and Other Communication Disorders	2021 to 2023	$984,939	April 11, 2019	March 31, 2024	MIDDLEBROOKS, JOHN C	reporter.nih.gov
Regulation of MPNST pathogenesis by Chromosome 8 gene, UBR5	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$939,675	January 18, 2024	December 31, 2028	HIRBE, ANGELA CHRISTINE	reporter.nih.gov
Modeling neurofibromatosis-1 disease heterogeneity to optimize risk assessment and treatment	NIH	National Institute of Neurological Disorders and Stroke	2025	$877,001	May 2, 2025	April 30, 2033	GUTMANN, DAVID H	reporter.nih.gov
Neurobiology and Treatment of Reading Disability in NF1	NIH	Eunice Kennedy Shriver National Institute of Child Health & Human Development	2022	$864,481	June 1, 2022	January 31, 2023	CUTTING, LAURIE E	reporter.nih.gov
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2024	$827,108	January 1, 2021	December 31, 2025	KISSIL, JOSEPH	reporter.nih.gov
Targeting Complement 5a-Mediated Immunoregulation for Neurofibroma Therapy	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2022	$788,678	September 1, 2019	February 28, 2023	WU, JIANQIANG	reporter.nih.gov
ARF6 function in cancers driven by RAS hyperactivation	NIH	National Cancer Institute	2021 to 2023	$741,981	July 3, 2018	August 31, 2025	YOO, JAE HYUK	reporter.nih.gov
T cells in neurofibroma pathogenesis and malignanttransformation	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2025	$737,024	June 1, 2022	May 31, 2027	RHODES, STEVEN DAVID	reporter.nih.gov
Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden	NIH	National Institute of Neurological Disorders and Stroke	2025	$734,542	June 20, 2025	May 30, 2027	PRADA, CARLOS ENRIQUE	reporter.nih.gov
Redox Signaling in Neurofibromatosis	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2023	$710,450	February 15, 2019	February 2, 2023	FRANCO, MARIA CLARA	reporter.nih.gov
Development of a Novel AAV9 Gene Replacement Therapy for Neurofibromatosis Type 2	NIH	National Institute of Neurological Disorders and Stroke	2024	$699,559	August 1, 2024	December 31, 2025	HENWOOD, NICOLE	reporter.nih.gov
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2023	$689,153	September 1, 2022	February 28, 2025	MATTSON-HOSS, MICHELLE	reporter.nih.gov
F-box ubiquitin ligases destabilize neurofibromin	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2022	$689,062	September 1, 2018	August 31, 2023	CLAPP, DAVID W	reporter.nih.gov
Vestibular dysfunction in patients with sporadic vestibular schwannomas and NF2-related schwannomatosis.	NIH	National Institute on Deafness and Other Communication Disorders	2025	$620,240	May 1, 2025	April 30, 2030	LEWIS, RICHARD F	reporter.nih.gov
Cell of Origin and the Roles of Tumor Microenvironment in Neurofibroma Development and Therapeutics	NIH	National Cancer Institute	2021 to 2022	$617,376	August 3, 2012	January 26, 2024	LE, LU	reporter.nih.gov
Mechanisms of hyperactive Ras signaling in craniofacial and dental diseases	NIH	National Institute of Dental & Craniofacial Research	2025	$600,029	March 10, 2025	February 28, 2030	KLEIN, OPHIR D	reporter.nih.gov
The role of Neurofibromin 2 in heart failure	NIH	National Heart, Lung, and Blood Institute	2022	$581,821	June 15, 2022	May 31, 2023	DEL RE, DOMINIC P	reporter.nih.gov
Investigation of a novel molecular driver of schwannoma nerve sheath tumors	NIH	National Institute of Neurological Disorders and Stroke	2025	$578,372	July 15, 2025	June 30, 2030	SOLOMON, DAVID A.	reporter.nih.gov
Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$574,838	June 1, 2024	May 31, 2027	PLOTKIN, SCOTT R	reporter.nih.gov
Engineering protease biomarkers to guide surgical therapy for vestibular schwannoma and Neurofibromatosis Type 2	NIH	National Institute on Deafness and Other Communication Disorders	2023 to 2025	$567,370	January 1, 2023	December 31, 2027	REN, YIN	reporter.nih.gov
Deciphering the role of cancer pain-associated neuronal activity in driving malignancies	NIH	National Cancer Institute	2025	$513,127	September 9, 2025	August 31, 2030	PAN, YUAN	reporter.nih.gov
Tumor-Mediated Hearing Loss in Neurofibromatosis Type II	NIH	National Institute on Deafness and Other Communication Disorders	2021 to 2023	$501,293	December 1, 2018	November 30, 2024	DINH, CHRISTINE THUYVAN	reporter.nih.gov
Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency	NIH	National Institute of Neurological Disorders and Stroke	2021 to 2022	$482,503	September 20, 2021	March 31, 2024	MATTSON-HOSS, MICHELLE	reporter.nih.gov
Quantitative MRI for Pediatric Optic Pathway Glioma Treatment Response	NIH	National Cancer Institute	2021	$446,107	June 17, 2020	May 31, 2022	AVERY, ROBERT ANDREW	reporter.nih.gov
Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism	NIH	National Institute of Neurological Disorders and Stroke	2022	$435,120	March 1, 2022	June 30, 2022	TOMCHIK, SETH M	reporter.nih.gov
Novel targets of treatment for NF1-mutant melanoma	NIH	National Cancer Institute	2021 to 2022	$431,866	August 2, 2021	July 31, 2023	OSMAN, IMAN	reporter.nih.gov
Novel small-molecule therapeutics for malignant peripheral nerve sheath tumor	NIH	National Cancer Institute	2022	$400,000	September 1, 2022	August 31, 2024	SHIH, TSUNG-CHIEH	reporter.nih.gov
Characterizing the cell-of-origin for NF1 dystrophic scoliosis	NIH	National Institute of Arthritis and Musculoskeletal and Skin Diseases	2024 to 2025	$369,600	April 1, 2024	March 31, 2026	ELEFTERIOU, FLORENT	reporter.nih.gov
Defining the Extrinsic and Intrinsic Mechanisms of Vision Loss in Optic Glioma	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$357,836	July 15, 2024	June 30, 2029	TANG, YUNSHUO CAROLINE	reporter.nih.gov
Improving Strategies to Determine Pathogenicity of Variants of Uncertain Significance	NIH	National Human Genome Research Institute	2021 to 2022	$312,318	April 1, 2019	January 31, 2023	BALDRIDGE, DUSTIN M	reporter.nih.gov
The Impact of Nf1 Mutation on Oligodendrocyte Development and Fine Motor Learning	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$296,000	July 1, 2024	May 31, 2028	LOPEZ JUAREZ, ALEJANDRO	reporter.nih.gov
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2	NIH	National Institute of Neurological Disorders and Stroke	2021	$289,588	May 5, 2021	December 31, 2022	KISSIL, JOSEPH	reporter.nih.gov
Increasing NF1 Expression as a Treatment for NF1 Haploinsufficiency	NIH	National Institute of Neurological Disorders and Stroke	2021	$256,597	July 15, 2021	September 30, 2022	SARNOFF, HERB	reporter.nih.gov
Metabotropic glutamate receptor 7 as a potential genetic modifier of cognitive deficits in neurofibromatosis	NIH	National Institute of Neurological Disorders and Stroke	2025	$237,399	April 1, 2025	March 31, 2027	NISWENDER, COLLEEN M	reporter.nih.gov
Mechanisms of Nf1 Pathophysiology Underlying Hyperactivity	NIH	National Institute of Neurological Disorders and Stroke	2021	$236,761	May 1, 2017	April 1, 2022	TOMCHIK, SETH M	reporter.nih.gov
Modeling Neurofibromatosis Type 2 with Inner Ear Organoids	NIH	National Institute on Deafness and Other Communication Disorders	2021 to 2024	$204,099	January 31, 2020	January 30, 2025	STEINHART, MATTHEW REED	reporter.nih.gov
Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)	NIH	National Institute of Neurological Disorders and Stroke	2021	$198,603	September 30, 2020	July 31, 2022	LUO, SUSAN X	reporter.nih.gov
INVESTIGATING THE MOLECULAR MECHANISMS OF DIFFERENTIATION FAILURE IN NF2 MUTANT NEUROEPITHELIAL STEM CELLS	NIH	National Institute of Neurological Disorders and Stroke	2025	$190,485	February 4, 2025	January 31, 2030	TAILOR, JIGNESH	reporter.nih.gov
Retinal circuit integration and degeneration in Neurofibromatosis type-1	NIH	National Eye Institute	2025	$172,818	January 1, 2025	December 31, 2026	YOUNG, BRENT KEVIN	reporter.nih.gov
Investigating the Role of Somatic Mutations in Neurofibromatosis Brain	NIH	National Institute of Neurological Disorders and Stroke	2023 to 2024	$144,364	July 1, 2023	June 30, 2025	SNELLINGS, DANIEL	reporter.nih.gov
Molecular Mechanisms of ADHD in Neurofibromatosis Type 1	NIH	National Institute of Mental Health	2021 to 2024	$137,825	July 1, 2020	March 31, 2024	DROZD, HAYLEY P	reporter.nih.gov
Activating Protein Expression Using Antisense Oligonucleotides	NIH	National Institute of General Medical Sciences	2021 to 2022	$136,192	February 1, 2021	January 31, 2023	KARTJE, ZACHARY	reporter.nih.gov
The Role of HER3 and IGF1R, through Non-Classical Ras Signaling, on Malignant Peripheral Nerve Sheath Tumor Progression	NIH	National Cancer Institute	2021 to 2023	$132,198	January 1, 2020	May 31, 2023	DOUTT, SHANNON WEBER	reporter.nih.gov
Neurofibromin 1 as a novel regulator of lipid metabolism	NIH	National Institute of Neurological Disorders and Stroke	2024 to 2025	$100,512	September 20, 2024	August 31, 2026	GATESMAN, TAYLOR	reporter.nih.gov
Dissecting Mechanism of Neurofibromin Regulation in the Context of Sporadic Cancers and Neurofibromatosis Type 1	NIH	National Cancer Institute	2025	$94,091	December 4, 2024	November 30, 2028	SITTON, MADELEINE JANETTE	reporter.nih.gov
Intratumoral plasma cells in MPNST response to CDK4/6 targeted therapy and sensitization to immune checkpoint blockade	NIH	National Cancer Institute	2023 to 2024	$70,262	June 1, 2023	May 31, 2026	LINGO, JOSHUA J	reporter.nih.gov
Metabolomic Analysis of Primary Human Meningioma and Schwannoma following Radiation Therapy: A Novel Approach to Identify Targetable Radiosensitive Pathways	NIH	National Cancer Institute	2022	$69,802	July 1, 2022	June 30, 2023	DOUGHERTY, MARK C	reporter.nih.gov
Gene Therapy for the Treatment of Neurofibromatosis Type I (NF1)	NIH	National Cancer Institute	2022 to 2023	$68,938	August 1, 2022	July 31, 2024	SITTON, MADELEINE JANETTE	reporter.nih.gov
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2	NIH	National Institute of Neurological Disorders and Stroke	2021	$57,529	January 1, 2021	March 5, 2021	KISSIL, JOSEPH	reporter.nih.gov
Evaluating the role of T cells in NF1-peripheral nerve sheath tumor (PNST) progression	NIH	National Cancer Institute	2025	$41,905	July 21, 2025	July 20, 2027	WHITE, EMILY ELIZABETH	reporter.nih.gov
Neuronal Mechanisms of Neurofibromin-Mediated Modulation of Metabolic Homeostasis	NIH	National Institute of Neurological Disorders and Stroke	2022 to 2023	$30,688	July 1, 2022	May 19, 2023	BOTERO, VALENTINA	reporter.nih.gov
Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism	NIH	National Institute of Neurological Disorders and Stroke	2022	$27,380	March 1, 2022	April 1, 2022	TOMCHIK, SETH M	reporter.nih.gov

Organizations

Organization	Place	NIH awards	NIH amount	NSF amount
Washington University	Saint Louis, MO	7	$9.5 million	$0
Cincinnati Childrens Hosp Med CTR	Cincinnati, OH	6	$9.2 million	$0
Indiana University Indianapolis	Indianapolis, IN	9	$6 million	$0
Massachusetts General Hospital	Boston, MA	4	$5.8 million	$0
University of Minnesota	Minneapolis, MN	2	$4.4 million	$0
Children's Research Institute	Washington, DC	2	$3.5 million	$0
University of Iowa	Iowa City, IA	5	$3.4 million	$0
Stanford University	Stanford, CA	3	$3.3 million	$0
University of California, San Francisco	San Francisco, CA	3	$3.1 million	$0
Sloan-Kettering Inst Can Research	New York, NY	1	$3.1 million	$0
H. Lee Moffitt Cancer CTR & Res Inst	Tampa, FL	3	$2.8 million	$0
Children's Hosp of Philadelphia	Philadelphia, PA	2	$2.6 million	$0
Baylor College of Medicine	Houston, TX	2	$2.1 million	$0
Merlin Therapeutics INC	King Of Prussia, PA	2	$2 million	$0
Brigham and Women's Hospital	Boston, MA	1	$1.9 million	$0
Medical University of South Carolina	Charleston, SC	2	$1.9 million	$0
Rutgers Biomedical and Health Sciences	Newark, NJ	1	$1.8 million	$0
Johns Hopkins University	Baltimore, MD	1	$1.7 million	$0
University of Tennessee Health Sci CTR	Memphis, TN	1	$1.7 million	$0
University of TX MD Anderson Can CTR	Houston, TX	2	$1.7 million	$0
Icahn School of Medicine at Mount Sinai	New York, NY	1	$1.6 million	$0
University of Chicago	Chicago, IL	1	$1.5 million	$0
Infixion Bioscience, Inc.	Escondido, CA	3	$1.4 million	$0
Medical College of Wisconsin	Milwaukee, WI	1	$1.4 million	$0
Augusta University	Augusta, GA	1	$1.3 million	$0
The University of Central Florida Board of Trustees	Orlando, FL	1	$1.2 million	$0
Vanderbilt University	Nashville, TN	2	$1.1 million	$0
University of California-Irvine	Irvine, CA	1	$984,939	$0
University of Nebraska Medical Center	Omaha, NE	1	$741,981	$0
Lurie Children's Hospital of Chicago	Chicago, IL	1	$734,542	$0
Oregon State University	Corvallis, OR	1	$710,450	$0
Massachusetts Eye and Ear Infirmary	Boston, MA	1	$620,240	$0
Ut Southwestern Medical Center	Dallas, TX	1	$617,376	$0
Cedars-Sinai Medical Center	Los Angeles, CA	1	$600,029	$0
Rbhs-New Jersey Medical School	Newark, NJ	1	$581,821	$0
Ohio State University	Columbus, OH	1	$567,370	$0
University of Miami School of Medicine	Coral Gables, FL	1	$501,293	$0
University of Florida	Gainesville, FL	1	$435,120	$0
New York University School of Medicine	New York, NY	1	$431,866	$0
Kibio Inc.	Davis, CA	1	$400,000	$0
Scripps Florida	Jupiter, FL	3	$321,670	$0
The University of Texas Rio Grande Valley	Edinburg, TX	1	$296,000	$0
Mulberry Biotherapeutics, Inc.	Wellesley, MA	1	$198,603	$0
Boston Children's Hospital	Boston, MA	1	$144,364	$0
Univ of Massachusetts Med SCH Worcester	Worcester, MA	1	$136,192	$0
University of Pittsburgh at Pittsburgh	Pittsburgh, PA	1	$100,512	$0
Duke University	Durham, NC	1	$68,938	$0

Funding by fiscal year

Fiscal year	NIH awards	NIH amount	NSF amount
2025	44	$19,477,601	$0
2024	46	$18,326,439	$0
2023	47	$18,861,960	$0
2022	49	$19,339,256	$0
2021	36	$13,908,800	$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunity	Number	Agency	Listing	Closes	Award ceiling	Why it matches
Functional Target Validation for Alzheimer's Disease-Related Dementias	RFA-NS-26-034	NIH	93.853	November 6, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)	PAR-27-007	NIH	93.853	November 10, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)	RFA-NS-26-001	NIH	93.853	November 10, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)	RFA-NS-26-030	NIH	93.853	November 10, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)	PAR-25-369	NIH	93.853	November 18, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)	PAR-25-371	NIH	93.853	November 18, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)	PAR-25-052	NIH	93.853	November 19, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)	RFA-AT-25-003	NIH	93.853	November 23, 2026	$375,000	Same assistance listing 93.853 as 49 awards here
Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)	RFA-OD-27-008	NIH	93.853	December 2, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Emerging Global Leader Award (K43 Independent Clinical Trial Required)	PAR-24-295	NIH	93.853	December 3, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)	PAR-24-296	NIH	93.853	December 3, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)	RFA-OD-24-011	NIH	93.853	December 4, 2026	Not listed	Same assistance listing 93.853 as 49 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	PAR-24-214	NIH	93.853	January 7, 2027	$375,000	Same assistance listing 93.853 as 49 awards here
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)	RFA-NS-25-023	NIH	93.853	January 15, 2027	$350,000	Same assistance listing 93.853 as 49 awards here
HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)	RFA-DA-28-011	NIH	93.853	January 26, 2027	Not listed	Same assistance listing 93.853 as 49 awards here
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed)	RFA-DA-28-012	NIH	93.853	January 26, 2027	Not listed	Same assistance listing 93.853 as 49 awards here
Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)	PAR-24-268	NIH	93.853	January 27, 2027	$500,000	Same assistance listing 93.853 as 49 awards here
Translational Neural Devices (R61/R33 - Clinical Trial Optional)	PAR-25-053	NIH	93.853	January 28, 2027	Not listed	Same assistance listing 93.853 as 49 awards here
BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18 - Clinical Trial Not Allowed)	RFA-NS-24-031	NIH	93.853	January 28, 2027	$750,000	Same assistance listing 93.853 as 49 awards here
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System	RFA-NS-28-006	NIH	93.853	January 28, 2027	Not listed	Same assistance listing 93.853 as 49 awards here

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.